MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) With Oncogenic Driver Mutations: New Results From the Global IMMUNOTARGET Registry

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.342
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Hot Spot Mutations in Finnish Non-Small Cell Lung Cancers

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2016English

New Driver Mutations Detected in NSCLC

Cancer Discovery
Oncology
2016English

TG4010 Immunotherapy Combined With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase IIb Results of the TIME Study

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2014English

P2.04-29 Preliminary Results With Tislelizumab in Chinese Patients With Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-13 Prognosis of Non-Driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

FDA Approves Breakthrough Immunotherapy for Patients With Non-Small-Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

P1.01-53 Bone Metastases and Efficacy of Immunotherapy in Patients With Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Quantifying the Benefit of Non-Small-Cell Lung Cancer Immunotherapy

The Lancet
Medicine
2019English

PCN134 Patient Preferences for Non-Small Cell Lung Cancer (NSCLC) Treatments

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy